Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab After Expanded Endoscopic Sinus Surgery in Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
ChiCTR2500109464Phase 4Recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Hunan Provincial People's Hospital. Primary endpoints: Olfactory Sniffin' Sticks score at 12 months, Lund-Kennedy score at 12 months and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on ChiCTR2500109464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109464.